Marimastat

Marimastat
Clinical data

Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Development terminated?
Identifiers
IUPAC name N-[2,2-Dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4- methyl-pentanamide
CAS Number	154039-60-8^Y
PubChem CID	119031
IUPHAR/BPS	5220
DrugBank	DB00786^N
ChemSpider	106358^N
UNII	D5EQV23TDS
ChEMBL	CHEMBL279785^N
PDB ligand	097 (PDBe, RCSB PDB)
Chemical and physical data
Formula	C₁₅H₂₉N₃O₅
Molar mass	331.408 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
InChI InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1^N Key:OCSMOTCMPXTDND-OUAUKWLOSA-N^N
^NY (what is this?) (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.^[1]^[2]

Marimastat performed poorly in clinical trials,^[3] and development was terminated.

References

↑ "Marimastat". National Cancer Institute.
↑ Millar, AW; Brown PD; Moore J; et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol. 45 (1): 21–6. PMC 1873993 . PMID 9489589. doi:10.1046/j.1365-2125.1998.00639.x.
↑ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol. 22 (23): 4683–90. PMID 15570070. doi:10.1200/JCO.2004.08.054.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.